Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B Ruling: Little Commercial Impact, Big Policy Implications

This article was originally published in The Tan Sheet

Executive Summary

The court ruling overturning FDA's restricted distribution of the emergency contraceptive Plan B could have a number of implications for the biopharma industry - ranging from a near-term impact on confirmation of Obama administration nominees to a longer-term curbing of creative product risk management activities

Related Content

FDA Will Wait To Act On Plan B Petition Despite Contempt Complaint
FDA Report Calls For Dedicated Office Component For Dispute Management
FDA Reorganization Elevates Scientific And Food Safety Priorities
FDA Reorganization Elevates Scientific And Food Safety Priorities
With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics
Sebelius Plans To Leave Plan B Decision To Science
FDA Scientists Say Plan B Decision-Makers At CDER “Should Be Removed”
Plan B Ruling Sets A Precedent That Could Give FDA Pause
Bush’s “Conscience” Rule Limiting Plan B Access On HHS Chopping Block
Plan B launches “strong”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts